{"id":"https://openalex.org/W2597635018","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.tps9103","title":"CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM).","display_name":"CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM).","publication_year":2013,"publication_date":"2013-05-20","ids":{"openalex":"https://openalex.org/W2597635018","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.tps9103","mag":"2597635018"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2013.31.15_suppl.tps9103","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.tps9103","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.15_suppl.tps9103","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5084967339","display_name":"Frank Stephen Hodi","orcid":"https://orcid.org/0000-0001-6825-091X","observed_orcids":["https://orcid.org/0000-0001-6825-091X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"F. Stephen Hodi","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103952920","display_name":"Asim Amin","orcid":"https://orcid.org/0009-0001-0011-7298","observed_orcids":["https://orcid.org/0009-0001-0011-7298"]},"institutions":[{"id":"https://openalex.org/I4210100342","display_name":"Levine Cancer Institute","ror":"https://ror.org/0174nh398","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334069289","https://openalex.org/I4210100342"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Asim Amin","raw_affiliation_strings":["Levine Cancer Institute, Charlotte, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Levine Cancer Institute, Charlotte, NC","institution_ids":["https://openalex.org/I4210100342"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078069424","display_name":"Yvonne M. Saenger","orcid":"https://orcid.org/0000-0001-7074-2681","observed_orcids":["https://orcid.org/0000-0001-7074-2681"]},"institutions":[{"id":"https://openalex.org/I98704320","display_name":"Icahn School of Medicine at Mount Sinai","ror":"https://ror.org/04a9tmd77","country_code":"US","type":"education","lineage":["https://openalex.org/I1320796813","https://openalex.org/I98704320"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yvonne M. Saenger","raw_affiliation_strings":["Mount Sinai School of Medicine, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mount Sinai School of Medicine, New York, NY","institution_ids":["https://openalex.org/I98704320"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019044309","display_name":"Gregory K. Pennock","orcid":"https://orcid.org/0009-0008-5263-0625","observed_orcids":["https://orcid.org/0009-0008-5263-0625"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gregory K. Pennock","raw_affiliation_strings":["M. D. Anderson Cancer Center, Orlando, Orlando, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"M. D. Anderson Cancer Center, Orlando, Orlando, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031957382","display_name":"Troy H. Guthrie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095251","display_name":"Baptist Cancer Center","ror":"https://ror.org/00skc2q21","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210095251"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Troy H. Guthrie","raw_affiliation_strings":["Baptist Cancer Institute, Jacksonville, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Baptist Cancer Institute, Jacksonville, FL","institution_ids":["https://openalex.org/I4210095251"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090769354","display_name":"April K.S. Salama","orcid":"https://orcid.org/0000-0002-8105-5374","observed_orcids":["https://orcid.org/0000-0002-8105-5374"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4390039326","display_name":"Duke Cancer Institute","ror":"https://ror.org/04vt65461","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876","https://openalex.org/I4390039326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"April K. Salama","raw_affiliation_strings":["Duke Cancer Institute, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke Cancer Institute, Durham, NC","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4390039326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050428554","display_name":"Lawrence E. Flaherty","orcid":"https://orcid.org/0000-0002-2132-902X","observed_orcids":["https://orcid.org/0000-0002-2132-902X"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lawrence E. Flaherty","raw_affiliation_strings":["Wayne State University School of Medicine, Detroit, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wayne State University School of Medicine, Detroit, MI","institution_ids":["https://openalex.org/I185443292"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047266965","display_name":"Henry B. Koon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799343972","display_name":"University Hospitals of Cleveland","ror":"https://ror.org/0130jk839","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799343972"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Henry B. Koon","raw_affiliation_strings":["University Hospitals of Cleveland, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospitals of Cleveland, Cleveland, OH","institution_ids":["https://openalex.org/I2799343972"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056670989","display_name":"David H. Lawson","orcid":"https://orcid.org/0000-0002-9474-8321","observed_orcids":["https://orcid.org/0000-0002-9474-8321"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David H. Lawson","raw_affiliation_strings":["Emory University School of Medicine, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Emory University School of Medicine, Atlanta, GA","institution_ids":["https://openalex.org/I150468666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084480627","display_name":"Montaser F. Shaheen","orcid":"https://orcid.org/0009-0006-1542-2267","observed_orcids":["https://orcid.org/0009-0006-1542-2267"]},"institutions":[{"id":"https://openalex.org/I4390039284","display_name":"UNM Comprehensive Cancer Center","ror":"https://ror.org/05kx2e072","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I169521973","https://openalex.org/I4390039284"]}],"countries":["MX","US"],"is_corresponding":false,"raw_author_name":"Montaser F. Shaheen","raw_affiliation_strings":["University of New Mexico Cancer Center, Albuquerque, NM"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of New Mexico Cancer Center, Albuquerque, NM","institution_ids":["https://openalex.org/I4390039284"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064085145","display_name":"\u00c1gnes Balogh","orcid":"https://orcid.org/0009-0003-4656-8320","observed_orcids":["https://orcid.org/0009-0003-4656-8320"]},"institutions":[{"id":"https://openalex.org/I4210137003","display_name":"Bristol-Myers Squibb (Belgium)","ror":"https://ror.org/03c09ma81","country_code":"BE","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210137003"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Agnes Balogh","raw_affiliation_strings":["Bristol-Myers Squibb, Braine-l'Alleud, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Braine-l'Alleud, Belgium","institution_ids":["https://openalex.org/I4210137003"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032777196","display_name":"Cyril Konto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cyril Konto","raw_affiliation_strings":["Bristol-Myers Squibb, Wallingford, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Wallingford, CT","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060495866","display_name":"Steven J O'Day","orcid":"https://orcid.org/0009-0005-5345-5417","observed_orcids":["https://orcid.org/0009-0005-5345-5417"]},"institutions":[{"id":"https://openalex.org/I4210100502","display_name":"Beverly Hills Cancer Center","ror":"https://ror.org/00j1j3213","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210100502"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven O'Day","raw_affiliation_strings":["The Beverly Hills Cancer Center, Beverly Hills, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Beverly Hills Cancer Center, Beverly Hills, CA","institution_ids":["https://openalex.org/I4210100502"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":13,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"31","issue":"15_suppl","first_page":"TPS9103","last_page":"TPS9103"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9883000254631042,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9883000254631042,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.007499999832361937,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vemurafenib","display_name":"vemurafenib","score":0.996999979019165},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":1.0},{"id":"https://openalex.org/keywords/braf-v600-mutation","display_name":"BRAF V600 mutation","score":0.9179999828338623},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.9940000176429749},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.5199999809265137},{"id":"https://openalex.org/keywords/braf-inhibitors","display_name":"BRAF inhibitors","score":0.7429999709129333},{"id":"https://openalex.org/keywords/sequential-therapy","display_name":"sequential therapy","score":0.5019999742507935},{"id":"https://openalex.org/keywords/drug-related-adverse-events","display_name":"drug-related adverse events","score":0.7319999933242798},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.8159999847412109},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.4819999933242798},{"id":"https://openalex.org/keywords/disease-progression","display_name":"disease progression","score":0.4300000071525574},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.5099999904632568},{"id":"https://openalex.org/keywords/immune-related-skin-toxicity","display_name":"immune-related skin toxicity","score":0.3959999978542328},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.6309999823570251},{"id":"https://openalex.org/keywords/joint-pain","display_name":"joint pain","score":0.9129999876022339}],"concepts":[{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.9333075881004333},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8946585655212402},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.8516117930412292},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6518441438674927},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.6336597800254822},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.605906069278717},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5615583658218384},{"id":"https://openalex.org/C2780964509","wikidata":"https://www.wikidata.org/wiki/Q416975","display_name":"Dacarbazine","level":3,"score":0.4886930286884308},{"id":"https://openalex.org/C2778830669","wikidata":"https://www.wikidata.org/wiki/Q3011604","display_name":"Dabrafenib","level":5,"score":0.4751988649368286},{"id":"https://openalex.org/C2778472372","wikidata":"https://www.wikidata.org/wiki/Q7833138","display_name":"Trametinib","level":4,"score":0.46692582964897156},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44279366731643677},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.42232176661491394},{"id":"https://openalex.org/C2777389519","wikidata":"https://www.wikidata.org/wiki/Q425088","display_name":"Temozolomide","level":3,"score":0.4147256910800934},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3244211971759796},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.32395318150520325},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.22224730253219604},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.21313732862472534},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.1893250048160553},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.18589076399803162},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.17545828223228455},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.1281280815601349},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2013.31.15_suppl.tps9103","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.tps9103","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.15_suppl.tps9103","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8500000238418579,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2236199583","https://openalex.org/W2884253050","https://openalex.org/W2058633833","https://openalex.org/W2023835753","https://openalex.org/W2571465038","https://openalex.org/W4223510352","https://openalex.org/W1453870474","https://openalex.org/W2219112405","https://openalex.org/W2791537298","https://openalex.org/W3006719485"],"abstract_inverted_index":{"TPS9103":[0],"Background:":[1],"Ipilimumab":[2],"(Ipi),":[3],"a":[4,22,71,130,175,213],"fully":[5],"human":[6],"monoclonal":[7],"antibody":[8],"that":[9,78],"binds":[10],"to":[11,148,266,329],"cytotoxic":[12],"T-lymphocyte":[13],"antigen-4":[14],"expressed":[15],"on":[16,225,261,271],"T":[17],"cells,":[18],"and":[19,57,98,117,123,126,179,197,313],"vemurafenib":[20],"(Vem),":[21],"small":[23],"molecule":[24],"inhibitor":[25],"of":[26,49,76,132,141,183,216,258,275,282,297,325,333,343],"BRAF":[27,81,153,176],"V600-mutated":[28,154],"kinase,":[29],"are":[30,129,190,328],"both":[31],"approved":[32],"treatments":[33],"for":[34,205,233,308,321],"AM.":[35,64,155],"Ipi":[36,92,146,226,262,272],"has":[37,66],"shown":[38,67],"improved":[39,68],"overall":[40],"survival":[41],"(OS)":[42],"in":[43,70,150],"two":[44],"randomized":[45,72],"phase":[46,73],"III":[47,74],"trials":[48],"patients":[50,77,151,160,165,221],"with":[51,91,112,152,171],"previously":[52,58,172],"treated":[53],"(3":[54],"mg/kg":[55,61,229],"monotherapy)":[56],"untreated":[59,173],"(10":[60],"plus":[62],"dacarbazine)":[63],"Vem":[65,113,119,142,204,251,284],"OS":[69],"trial":[75,347],"harbor":[79],"the":[80,139,256,279,289,295,298,331,341],"V600E":[82],"mutation.":[83],"The":[84,108,323],"most":[85,109],"common":[86,110],"drug-related":[87,336],"adverse":[88],"events":[89],"(AEs)":[90],"monotherapy":[93],"were":[94,102,114],"immune-related":[95],"GI":[96],"tract":[97],"skin":[99],"toxicities,":[100],"which":[101],"generally":[103],"manageable":[104],"using":[105],"treatment":[106],"guidelines.":[107],"AEs":[111],"arthralgia,":[115],"rash,":[116],"fatigue.":[118],"can":[120],"induce":[121],"rapid":[122],"substantial":[124],"responses,":[125],"resistance":[127],"mechanisms":[128],"focus":[131],"current":[133],"investigation.":[134],"This":[135],"study":[136,327],"will":[137,161,201,222,252,285,302,315],"evaluate":[138],"safety":[140],"lead-in":[143,299],"followed":[144,304,317],"by":[145],"(prior":[147],"resistance)":[149],"Methods:":[156],"An":[157],"estimated":[158],"45":[159],"be":[162,223,253,286,303,316],"enrolled.":[163],"Eligible":[164],"include":[166,340],"those":[167],"\u226518":[168],"years":[169],"old":[170],"AM,":[174],"V600":[177],"mutation,":[178],"an":[180],"ECOG":[181],"PS":[182],"0":[184],"or":[185,248,268],"1.":[186],"Major":[187],"exclusion":[188],"criteria":[189],"primary":[191],"ocular":[192],"melanoma,":[193],"active":[194],"brain":[195],"metastases,":[196],"autoimmune":[198],"disease.":[199],"Patients":[200,301],"initially":[202],"receive":[203],"6":[206],"weeks":[207,307,320],"(960":[208],"mg":[209],"twice":[210],"daily).":[211],"After":[212],"washout":[214],"period":[215],"3-10":[217],"days":[218],"(per":[219],"protocol),":[220],"initiated":[224],"at":[227,242,255,288,294],"10":[228],"(every":[230],"3":[231],"wk":[232,240],"4":[234],"doses,":[235],"then":[236],"once":[237],"every":[238,305,318],"12":[239,306,319],"beginning":[241],"week":[243],"24,":[244],"until":[245],"disease":[246,259,311],"progression":[247,260],"unacceptable":[249,269],"toxicity).":[250],"restarted":[254,287],"time":[257,265],"(no":[263],"minimum":[264,274],"restart)":[267],"toxicity":[270,309],"(restart":[273],"1":[276],"mo":[277],"after":[278],"last":[280,290],"dose":[281,291],"Ipi).":[283],"level":[292],"tolerated":[293],"end":[296],"phase.":[300],"and/or":[310],"progression,":[312],"subsequently":[314],"survival.":[322],"objectives":[324,339],"this":[326],"estimate":[330],"incidence":[332],"grade":[334],"3-4":[335],"AEs.":[337],"Exploratory":[338],"evaluation":[342],"efficacy":[344],"(OS).":[345],"Clinical":[346],"information:":[348],"NCT01673854.":[349]},"counts_by_year":[{"year":2019,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":2}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2025-10-10T00:00:00"}